These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 5937431)

  • 21. Drug treatment of peripheral vascular disease.
    Eberhardt RT; Coffman JD
    Heart Dis; 2000; 2(1):62-74. PubMed ID: 11728242
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Further studies of the incidence of coronary cardiopathy in subjects with peripheral arteriosclerotic obliterating arteriopathy. Clinico-statistical investigations of 1434 cases].
    Meciani L; Ricci G; Boeri S; Sabatini G; Biasi G; Biglioli P
    Minerva Cardioangiol; 1971 Mar; 19(3):147-51. PubMed ID: 5553463
    [No Abstract]   [Full Text] [Related]  

  • 23. [Prevention and therapy of peripheral arteriosclerotic circulatory disorders using anticoagulants].
    Egghart F
    Wien Med Wochenschr; 1973 Apr; 123(16):259-60. PubMed ID: 4701667
    [No Abstract]   [Full Text] [Related]  

  • 24. [On the differential diagnosis of arterial obliterating diseases of the upper extremities].
    Hofmeister L
    Munch Med Wochenschr; 1969 May; 111(22):1259-64. PubMed ID: 5819096
    [No Abstract]   [Full Text] [Related]  

  • 25. [Effect of various factors on peripheral blood vessel diseases].
    Skóra K; Popielska-Greblicka H; Noczyński L; Sokolowski J; Szyber P; Witkiewicz W
    Pol Tyg Lek; 1974 Jul; 29(26):1121-4. PubMed ID: 4848605
    [No Abstract]   [Full Text] [Related]  

  • 26. [Analysis of the pharmacodynamic properties of the nicotinic ester of 7-(2-hydroxyethyl)-theophylline. II. Cardiocirculatory effects in subjects with cerebral and peripheral angiopathies].
    De Gregorio G; Scaffidi L; Arcoraci A
    Cardiol Prat; 1971 Oct; 22(5):329-36. PubMed ID: 5136470
    [No Abstract]   [Full Text] [Related]  

  • 27. [Preliminary results of a clinical and instrumental study of cerebral and peripheral artery circulation with a new phytotherapeutic agent (Ginko biloba)].
    Saponaro A; Gambelli G; Cosentino F
    Minerva Med; 1971 Dec; 62(97):4838-49. PubMed ID: 5131191
    [No Abstract]   [Full Text] [Related]  

  • 28. [Drugs for the treatment of arterial blood flow disorders].
    Offerhaus L
    Ned Tijdschr Geneeskd; 1988 Jan; 132(2):51-3. PubMed ID: 3340217
    [No Abstract]   [Full Text] [Related]  

  • 29. [Personal experience on indirect long-term anticoagulant therapy in ambulatory peripheral chronic arteriosclersis obliterans patients].
    Raso AM; Silvestrini P
    Angiologia; 1968; 20(6):301-16. PubMed ID: 5747170
    [No Abstract]   [Full Text] [Related]  

  • 30. [Assessment of the action of Sadamine Polfa and Mydocalm Richter preparations as based on photoplethysmography].
    Chwistecki K; Bochenek W; Lawiński M
    Pol Tyg Lek; 1975 Dec; 30(50):2093-6. PubMed ID: 1197101
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical considerations and functional data on the use of the association of kallikrein and meso-inositol hexanicotinate in the therapy of obliterating arteriopathy].
    Blasi A; Licciardello M
    Clin Ter; 1966 Jul; 38(2):121-58. PubMed ID: 5990194
    [No Abstract]   [Full Text] [Related]  

  • 32. [Complamine in obliterating peripheral circulatory disorders].
    Kusztos D; Bereczky M; Fono J
    Med Monatsschr; 1970 Mar; 24(3):127-8. PubMed ID: 5436974
    [No Abstract]   [Full Text] [Related]  

  • 33. [Medium term treatment with suloctidil in obliterating arteriopathies of the lower limbs. Personal experience].
    Marongiu G; Dettori G; Gadeddu A; Noya G; Angius P; Biglioli P
    Minerva Cardioangiol; 1983; 31(7-8):407-10. PubMed ID: 6316206
    [No Abstract]   [Full Text] [Related]  

  • 34. [Chelates in the treatment of obliterating arterial diseases. (Preliminary report)].
    Brücknerová O; Tulácek J; Krojzl O
    Vnitr Lek; 1968 Sep; 14(9):841-5. PubMed ID: 4971419
    [No Abstract]   [Full Text] [Related]  

  • 35. [Clinical evaluation of pyridinolcarbamate effect on patients with obliterating atherosclerosis (author's transl)].
    Roztocil K; Oliva I; Linhart J; Prerovský I; Modr Z
    Cas Lek Cesk; 1976 Aug; 115(33-34):1051-5. PubMed ID: 975177
    [No Abstract]   [Full Text] [Related]  

  • 36. [FUNCTION TESTS AS PROGNOSTIC ELEMENTS IN GANGLIECTOMY IN TREATMENT OF CHRONIC PERIPHERAL OBLITERATING ARTERY DISEASES].
    VITTORI F; VITTORI C; SEGHEZZI R; TABORELLI G
    Minerva Chir; 1965 Mar; 20():228-33. PubMed ID: 14348645
    [No Abstract]   [Full Text] [Related]  

  • 37. [An assessment of the efficacy of intravenous monotherapy with the preparation solcoseryl in patients with arteriosclerosis obliterans of the vessels of the lower extremities].
    Luk'ianov IuV; Shlomin VV; Sokurenko GIu; Didenko IuP; Orlov NN; Kondrat'ev VM; Batalin IV
    Vestn Khir Im I I Grek; 2000; 159(3):81-4. PubMed ID: 10983350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy of a new pentoxifilline form-vasonit retard in the treatment of patients with obliterating diseases of the lower limbs arteries].
    Koshkin VM
    Ter Arkh; 2005; 77(4):83-4. PubMed ID: 15938541
    [No Abstract]   [Full Text] [Related]  

  • 39. [Behavior and significance of beta-thromboglobulin in chronic obliterating arteriopathy of the lower limbs. Preliminary research].
    Binaghi F; Valle E; Manconi E; Pitzus F
    Cardiologia; 1982 Nov; 27(11):1043-9. PubMed ID: 6085827
    [No Abstract]   [Full Text] [Related]  

  • 40. [Experience with treatment of obliterating atherosclerosis of the lower extremities with vitamin A and E under ambulatory conditions].
    Nechaev EB
    Vrach Delo; 1966 May; 5():128-9. PubMed ID: 5995479
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.